UNSPSC 51151626: Camylofin

This classification denotes a parasympatholytic with the molecular formula C19H32N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 340B6Q764V, chemically known as phenyldiethylaminoethyl-1-aminoacetic acid, isopentyl ester but generally known as camylofin, which bears US NIH Compound Identifier 5902. Camylofin most often comes in base and hydrochloride forms. European Medicines Agency schedules Camylofin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06068MIG.

UNSPSC 51151626 Camylofin is a Commodity code that captures pharmaceutical products and drug-related supplies procured by state and local health and human services agencies. Recent state and local opportunities under this code show solicitation for naloxone (opioid-reversal medication) and safe drug deactivation systems, alongside exploratory procurement for direct-to-manufacturer prescription programs. The buying bodies include county health departments and state health and human services commissions, which source these items to support community health initiatives, substance-abuse response, and pharmacy benefit management. Vendors must typically meet standard compliance requirements including E-Verify authorization, drug-free workplace certification, and insurance coverage (workers' compensation, general liability, professional liability), with contract terms running two to three years and options for renewal.

Solicitation activity under this code appears concentrated in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023, and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, requesting vendor information on capabilities for direct-to-manufacturer prescription programs and direct contracting with self-insured health plans, signaling exploratory procurement that will likely lead to a formal RFP. Both opportunities reflect state and local investment in pharmaceutical access and drug-related public health response, though the narrow recent-opportunity sample limits visibility into broader geographic or sectoral trends.